ALNY
NASDAQ
US
Alnylam Pharmaceuticals, Inc. - Common Stock
$318.85
▼ $-9.88
(-3.01%)
Vol 872K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$52.5B
P/E
1205.9
ROE
26.1%
Margin
1.4%
D/E
1071.05
Beta
0.32
52W
$206–$496
Wall Street Consensus
36 analysts · Apr 20267
Strong Buy
20
Buy
9
Hold
0
Sell
0
Strong Sell
75.0%
Buy Rating
Price Chart
Similar Stocks
AMGN
Amgen Inc
P/E 25.2
$176.3B
GILD
Gilead Sciences Inc
P/E 18.8
$152.3B
VRTX
Vertex Pharmaceuticals Inc
P/E 31.3
$115.0B
REGN
Regeneron Pharmaceuticals Inc
P/E 17.7
$81.1B
INSM
Insmed Inc
$37.1B
NTRA
Natera Inc
$31.7B
BIIB
Biogen Inc
P/E 16.0
$25.8B
UTHR
United Therapeutics Corp
P/E 16.5
$21.0B
RVMD
Revolution Medicines Inc
$15.4B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $1.15 | $0.82 | $-0.33 |
| Sep 2025 | $0.76 | $2.11 | +$1.35 |
| Jun 2025 | $-0.73 | $-0.51 | +$0.22 |
| Mar 2025 | $-1.03 | $-0.44 | +$0.59 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -274.2% | -274.2% | -274.2% | -274.2% | -274.2% | 26.1% |
| P/E (TTM) | — | — | — | — | — | 1205.90 |
| Net Margin | -8.6% | -13.0% | -13.0% | -13.0% | -13.0% | 1.4% |
| Gross Margin | 81.5% | 83.6% | 83.6% | 83.6% | 83.6% | 83.9% |
| D/E Ratio | 985.35 | 409.64 | 409.64 | 409.64 | 409.64 | 1071.05 |
| Current Ratio | 2.80 | 2.80 | 2.80 | 2.80 | 2.80 | 2.54 |
Key Ratios
ROA (TTM)
1.0%
P/S (TTM)
16.37
P/B
452.4
EPS (TTM)
$0.23
CF/Share
$-3.62
Rev Growth 3Y
+38.6%
52W High
$495.55
52W Low
$205.87
$205.87
52-Week Range
$495.55
How does ALNY compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ALNY valuation vs Biotechnology peers
P/E ratio
1205.9
▲
6321%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
16.4
▲
27%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
452.4
▲
18290%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ALNY profitability vs Biotechnology peers
ROE
26.1%
▲
139%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
1.4%
▲
100%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
83.9%
▲
7%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
1.0%
▲
102%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
ALNY financial health vs Biotechnology peers
D/E ratio
1071.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.5
▼
43%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.3
▼
67%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ALNY fundamentals radar
ALNY
Peer median
Industry
ALNY profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio